We hold an exclusive global license from the University of Tokyo and have secured key international patents. Our team blends proven leadership with deep scientific and clinical expertise.
With only the initial breast cancer indication, we project peak sales exceeding $1.5 billion. Multiple follow-on indications and novel delivery routes multiply that upside.